Review Article

Mycobacterial PE/PPE Proteins at the Host-Pathogen Interface

Samantha L. Sampson

Section of Microbiology, Centre for Respiratory Infection, Imperial College London, Armstrong Road, London SW7 2AZ, UK

Correspondence should be addressed to Samantha L. Sampson, ssampson@imperial.ac.uk

Received 30 September 2010; Accepted 23 December 2010

Copyright © 2011 Samantha L. Sampson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The mycobacterial PE/PPE proteins have attracted much interest since their formal identification just over a decade ago. It has been widely speculated that these proteins may play a role in evasion of host immune responses, possibly via antigenic variation. Although a cohesive understanding of their function(s) has yet to be established, emerging data increasingly supports a role for the PE/PPE proteins at multiple levels of the infectious process. This paper will delineate salient features of the families revealed by comparative genomics, bioinformatic analyses and genome-wide screening approaches and will summarise existing knowledge of subcellular localization, secretion pathways, and protein structure. These characteristics will be considered in light of findings on innate and adaptive host responses to PE/PPE proteins, and we will review the increasing body of data on B and T cell recognition of these proteins. Finally, we will consider how current knowledge and future explorations may contribute to a more comprehensive understanding of these intriguing proteins and their involvement in host pathogen interactions. Ultimately this information could underpin future intervention strategies, for example, in the area of new and improved diagnostic tools and vaccine candidates.

1. Introduction

Tuberculosis (TB) represents an ongoing threat to global health, with the current epidemic fuelled by HIV-co-infection and an increasing incidence of drug resistant strains of Mycobacterium tuberculosis [1]. Effective new interventions are urgently needed, and genes that are unique to mycobacteria may provide a starting point for developing these. The intriguing pe/ppe genes first attracted attention due to their genetically hypervariable nature [2, 3] and were initially exploited as informative molecular markers for mycobacterial strain typing [2, 4]. Shortly thereafter, the first *M. tuberculosis* genome sequence was completed, and it was revealed that these variable regions were in fact part of two extensive families encoding almost 200 putative proteins [5]. It is now known that these genes are unique to mycobacteria and are particularly abundant in pathogenic mycobacteria, such as *M. tuberculosis*. Naturally, the PE/PPE families have provoked much speculation, although we have yet to establish a complete understanding of their function. However, the advent of the mycobacterial genomic age, together with improved molecular tools and a deeper understanding of the immunopathogenesis of TB, has advanced our knowledge of these gene families and the potential functions of their encoded proteins.

2. PE/PPE Genomics

Analysis of the *M. tuberculosis* H37Rv genome sequence revealed the presence of two novel gene families that comprise almost 10% of the coding capacity of the genome [5]. These were designated the pe and ppe genes, after highly conserved Proline-Glutamate and Proline-Proline-Glutamate residues near the start of their encoded proteins. The proteins can be categorized into subgroups, encompassing members with highly variable length and sequence features (Figure 1) [5]. The relatively conserved N-terminal is approximately 110 amino acids (aa) and 180 aa in the PE and PPE families, respectively. The smallest members of both families consist of just this conserved domain, while other subclasses have additional C-terminal regions. The PE_PGRS (polymorphic GC-rich sequence) and PPE_MPTR (major polymorphic tandem repeat) subgroups possess C-terminal
The remarkable length and extensive sequence variation of the PE-PGRS and PPE-MPTR proteins appear to be primarily associated with lengthy stretches of GC-rich, imperfect triplet repeats within their associated genes. These are thought to be hotspots for recombination events and other mutations, including insertion of transposable elements [5, 6]. Other pe/ppe-associated sequence variation includes large sequence polymorphisms which appear to be mediated by highly homologous sequences in the conserved 5′ regions of pe/ppe genes [6]. Given the diverse mechanisms whereby pe/ppe polymorphisms can arise, together with the high potential for redundancy within the gene families, it is perhaps unsurprising that some pe/ppe genes vary extensively in clinical isolates [7–9]. Consequently, it has been speculated that these proteins represent a source of antigenic variation which allows the organism to escape antigen-specific host responses [5, 7, 8]. However, this hypothesis is as yet unproven, and there is little evidence to support rapid within-host diversification of these genes. Therefore, if the observed sequence variation is providing a source of antigenic diversity, the benefits of this are likely to operate on a population-wide scale, rather than within individual hosts. One study has demonstrated a moderately significant association of large sequence variation in pe_pgrs33 with noncavitary TB and case clustering [10]. However, further experimentation will be required to establish whether there is a causal link between these observations, and if so, to determine the underlying mechanistic basis. It is worth noting that while the pe_pgrs and ppe_mptr genes represent some of the most variable regions of the M. tuberculosis chromosome, it is an oversimplification to extend this to all pe/ppe family members, as some are in fact conserved across strains and species [11]. It is important to bear this distinction in mind when considering potential functional roles and to extrapolate experimental results with caution.

An increasing wealth of mycobacterial genome sequence data has advanced our knowledge of the sequence diversity and evolutionary history of the pe/ppe gene families. One comparative genomics study revealed that the evolution and major expansion of the pe/ppe families is closely associated with the esx regions [12]. These encode the so-called Type VII or ESX secretion systems, of which there are 5 in M. tuberculosis [13]. The best characterized of these is ESX-1, which has been implicated in mycobacterial virulence through the secretion of effectors such as EsxA and EsxB [14–16] (otherwise known as ESAT-6 (early secreted antigenic target of 6 kDa) and CFP-10 (culture filtrate protein of 10 kDa), resp.). Gay van Pittius and colleagues further showed that the most repetitive and variable family members represented by the PE-PGRS and PPE-MPTR subgroups are also the most phylogenetically recent. These subgroups are restricted to the pathogenic mycobacteria, and their massive expansion is closely associated with the most recently duplicated esx gene cluster, esx-5 [12]. These findings were suggestive of a functional link between the PE/PPE families and the ESX secretion systems. Indeed, it has since been demonstrated that the secretion of multiple PE/PPE family members is ESX-mediated [17–19].

### 3. Transcriptomics, Proteomics, Structure, and Subcellular Location

In tandem with burgeoning mycobacterial genome data, other “-omics” undertakings have shed light on certain aspects of the PE/PPE families. An exhaustive account of pe/ppe transcriptomics is beyond the scope of this paper. However, it is worth mentioning that a study of M. tuberculosis pe/ppe gene expression under 15 different conditions revealed that 128/169 pe/ppe genes analysed were differentially regulated [20]. Other groups have demonstrated that several pe/ppe genes are upregulated upon macrophage infection and in host tissues [21–24]. For example, Rachman et al. demonstrated that two pe genes (pe11, pe34), four pe_pgrs (pe_pgrs14, 33, 55 and 57), and three ppe_mptr genes (pe_pgrs54, 55 and 62) were all upregulated in human lung granulomas compared to in vitro grown bacteria [24]. Together with other published expression data, these results lend support to the idea that the pe/ppe genes play important functional roles in vivo.

Characterisation of regulatory and other mutants has revealed that subsets of pe/ppe genes are frequently among the genes whose expression levels are altered [25–27]. In one example, disruption of the virulence-associated PhoPR two-component regulator resulted in altered expression of at least 14 pe/ppe genes. These include pe_pgrs41, which demonstrated a striking 143-fold higher expression level in

---

**Figure 1:** Schematic representation of PE and PPE family subgroups. PE and PPE proteins possess relatively conserved N-terminal domains of approximately 110 aa and 180 aa, respectively. One subgroup of the PE family incorporates a characteristic “SVP” motif at approximately 350 aa. Both PE and PPE families can be divided into distinct subgroups on the basis of their variable C-terminal domains. The regions encoded by the Polymorphic GC-Rich Sequence (PGRS) of the pe family and the Major Polymorphic Tandem Repeats (MPTR) of the ppe family are major contributors to genome polymorphism.

| PE family | PPE family |
|-----------|------------|
| ~110 aa   | ~180 aa    |
| “PE-only” | GXXSVXXW   |
| ~110 aa   | PPE-SVP    |
|           | (up to ~470 aa) |
| Unique C-terminal region | Unique C-terminal region |
| (up to ~600 aa) | (up to ~560 aa) |
| PE-PGRS   | PPE-MPTR   |
| (up to ~1500 aa) | (up to ~3720 aa) |
wild type *M. tuberculosis* compared to the *phoP* mutant [26]. It has been demonstrated that selected *pe/ppe* genes may be differentially regulated in genotypically diverse clinical isolates [28–30]. For instance, Gao et al. examined gene expression in 10 clinical isolates of *M. tuberculosis* and found that 28 of the 77 *pe/ppe* genes included in the analysis showed variable expression [29]. There is also evidence for divergent regulation of specific family members within individual strains [31, 32]. This is exemplified by *pe_pgrs16* and *pe_pgrs26*, which are thought to be inversely regulated *in vitro* [31], although the mechanistic basis for this apparently coordinated expression is unclear. Taken together, available data does not support global regulation of *pe/ppe* gene expression, suggesting that there is likely to be a relatively high degree of plasticity in the *pe/ppe* expression repertoire. Although this may suggest that some *pe/ppe* genes are not required at all, this could also indicate that members within different subgroups of the family play subtly different functional roles and are required at different stages of disease.

The existence of multiple highly similar *pe/ppe* family members suggests a high potential for functional redundancy within subgroups. It is therefore not surprising that very few of these genes are essential for *in vitro* or *in vivo* growth, as demonstrated in a series of studies by Rubin and colleagues [33–35], Table S1 (see Table S1 in supplementary material available online at doi:10.1155/2011/497203). This high degree of redundancy contributes to one of the experimental challenges presented by this family, that is, that mutations in single *pe/ppe* genes may lack measurable phenotypes. However, there are some examples where this is not the case, and analysis of selected *pe/ppe* mutants has yielded important functional insights, as will be described below.

High-throughput proteomics-based studies have highlighted further challenges of working with *PE/PPE* proteins. The proteins are often very large, may be tightly associated with the cell wall, and can have limited proteolytic cleavage sites. These inherent properties may restrict the utility of some high-throughput proteomics approaches [18]. Nonetheless, using optimized growth conditions and sample preparation methods in conjunction with sensitive detection methodologies, some studies have successfully identified the subcellular localization of selected *PE/PPE* proteins in different mycobacterial strains and species (Table S1). For example, using proteolytic shaving of intact *Mycobacterium avium* subsp. *paratuberculosis* followed by LC-MS/MS, Newton et al. identified 2 PPE orthologues associated with the cell wall [36]. *PE_pGRS* and PPE orthologues were also identified in the cell membrane fraction of *Mycobacterium immunogenum* [37], and a recent detailed analysis of the *Mycobacterium marinum* capsule using cryoelectron microscopy in conjunction with LC-MS/MS demonstrated that 6/25 major cell surface proteins were members of the *PE/PPE* families [38]. Similarly, Målen et al. utilized MALDI-MS and LC-MS/MS to identify at least 7 and 16 *PE/PPEs* in the *M. tuberculosis* culture filtrate and envelope fractions, respectively [39, 40]. High-throughput proteomics approaches therefore suggest that cell wall/surface localization is a characteristic of several *PE/PPE* proteins. This has been corroborated by more focused studies which provide further substantial evidence indicating that numerous *PE/PPE* family members are associated with the bacterial cell wall [37, 38, 40–43]. These include PPE36 [42], PPE68 [41], PE_PGRS53 [44], PE_PGRS63 [43], and PPE_MPTR34, with further examples listed in Table S1. In some cases, results indicate surface exposure of these proteins [17, 44–47]. Although it has been proposed that *PE/PPE* proteins could form complex surface structures [48], this hypothesis has yet to be addressed experimentally.

To date, only one *PE/PPE* protein structure has been solved, perhaps reflecting the difficulty experienced with recovering stable, soluble recombinant *PE/PPE* proteins. Strategies used to successfully overcome this challenge include on-column refolding [49], use of mycobacterial host strains for expression [50], and coexpression of cognate *PE/PPE* pairs [51, 52]. Using the latter approach, Strong and coworkers successfully purified recombinant PE25/PPE41 and subsequently determined the crystal structure, which showed that the protein pair forms a stable 1:1 heterodimer [52]. The *PE/PPE* complex is reminiscent of the EssA/EssB complex, which could suggest common secretion pathways. Intriguingly, the PE25/PPE41 complex displays an apolar stripe on one face, which could represent a docking site for an as-yet unidentified bacterial or host target [52]. An attempted structure/function analysis revealed that the heterodimeric complex shares some features of signal transduction molecules [52], although this has yet to be explored experimentally. It is unknown whether the PE25/PPE41 structure is truly representative of the rest of the protein family. Indeed, it is unlikely that this structure can be extrapolated to family members which are not predicted to form heterodimers [53] or which demonstrate substantial variation in sequence length and content. The structural biology of *PE/PPE* proteins is therefore an area in much need of further development, as characterization and comparative analysis of additional *PE/PPE* structures could perhaps provide clues to their possible function. Another crucial step towards determining the function of the *PE/PPE* proteins will be identifying their interaction partners. In particular, determining host targets of these proteins could provide critical insights into their impact on host responses.

As mentioned above, the *PE/PPE* proteins are intimately associated with the ESX systems [12]. A functional link has been elucidated by the work of Abdallah and colleagues, who demonstrated that the ESX-5 apparatus mediates the secretion of multiple *PE/PPE* proteins, including members of the PE_PGRS and PPE_MPTR subsets [17, 18]. The ESX-5 locus is implicated in *M. marinum* virulence [17, 54], although it remains to be seen whether the secreted *PE/PPE* proteins play a central role in this. In addition, ESX-5-mediated *PE/PPE* secretion has yet to be demonstrated for *M. tuberculosis*. Of course, given the parallels with the EssA/EsxB complex and the close association with the ESX secretion apparatus, it is tempting to speculate that *PE/PPE* complexes (or the individual constituent proteins) could be virulence effectors secreted by ESX-5. Once again, caution should be exercised when extrapolating these results.
to other family members; it is worth noting that some PE/PPE proteins in fact possess functional N-terminal signal peptide cleavage sites [39]. It is therefore plausible that their secretion/localization may occur via other mechanisms, for example, the Sec-dependent export pathway. In support of this, several studies have reported cell-wall localization of PE/PPE proteins in *Mycobacterium smegmatis*, which lacks the ESX-5 region [44, 46, 47, 55]. In addition to the possible role of ESX-5, there is some evidence implicating ESX-1 in PE/PPE secretion. For example, the genes encoding PE35/PPE68 are situated within the *esx-1* region, and one study has suggested that PE35 secretion is ESX-1-dependent [19]. Others have demonstrated cell-wall association of PPE68 in *M. tuberculosis* [40, 41], and this protein also interacts with multiple components of the ESX-1 machinery [56, 57]. Interestingly, disruption of *ppe68* is associated with increased secretion of ESAT-6, leading to the suggestion that PPE68 may act as an ESX-1 gating protein [58], although this has yet to be experimentally verified.

Regardless of their secretion mechanism, several lines of evidence support surface localization of PE/PPE proteins (Table S1). Some PE/PPEs may be actively secreted or passively shed from the bacterium into the host cell milieu, and could even be released from host cells via exosomes [59]. Thus, they are ideally positioned to interact with the host immune system. Indeed, there is extensive evidence that they do so in ways that could have important consequences for the outcome of infection.

### 4. PE/PPEs Modulate Innate Immune Responses

There is mounting evidence that PE/PPE proteins interact with host components and thereby modulate and possibly subvert critical innate immune pathways. Ramakrishnan et al. provided the first definitive evidence that (at least some) PE-*pgrs* proteins are virulence factors, when they showed that two *M. marinum* *pe_pgrs* genes were required for survival in macrophages and granulomas [60]. Since then, the most extensively studied “exemplar” member of the *M. tuberculosis* PE-*pgrs* family, namely PE-*pgrs33*, has provided some insight into the numerous ways in which these proteins could modulate host immune responses. Detailed examination revealed that PE-*pgrs33* interacts directly with TLR-2, thereby mediating apoptosis and cytokine secretion [61]. Others have confirmed that PE-*pgrs33* promotes host cell apoptosis [59], and, in one study, necrosis [62]. Interestingly, sequence variants of PE-*pgrs33* and other PE-*pgrs* family members elicited differential effects [61]. PE-*pgrs11* and PE-*pgrs17* were also shown to interact with TLR-2, prompting maturation and activation of dendritic cells [63]. Independent studies have subsequently shown that PPE18 and an MPTR-containing domain of PPE-*mptr34* can also modulate host responses through TLR-2 [64, 65]. Although it has yet to be established if TLR-2 engagement is a common property of PE/PPE proteins, these results suggest that the additive host response to interaction with multiple PE/PPE proteins may be very complex, and could profoundly impact on the course of disease.

PE/PPE proteins can also influence macrophage function by other means. For example a BCG *pe_pgrs33* transposon mutant demonstrated reduced entry into macrophages [66], suggesting that PE-*pgrs33* may play a role in promoting macrophage uptake. In contrast to other bacteria, this may be advantageous for *M. tuberculosis* at the very early stage of infection, as it could promote dissemination and colonization of multiple organs. This strategy is only effective because the pathogen has evolved multiple strategies to overcome the hostile environment encountered within host cells. In this context, several PE/PPE proteins have been shown to facilitate, or be required for, *in vivo* survival [35, 60, 67, 68]. A key macrophage defence mechanism is phagosome maturation and acidification, which normally results in killing of intraphagosomal pathogens. However, *M. tuberculosis* is adept at subverting this pathway, and there is evidence that different PE/PPE family members may contribute to this. Selected PE/PPE family members have been implicated in the modulation of vacuole acidification [69–71]. For example, a high-throughput analysis of a *Mycobacterium bovis* BCG transposon mutant library identified four *pe_pgrs* mutants (pe_pgrs5, 28, 44, 59) and three *ppe_mptr* mutants (*ppe_mptr10*, 16, 21) that were enriched in acidified phagosomes. A more recent study showed that a *M. tuberculosis* *ppe54* transposon mutant was impaired in its ability to arrest phagosome maturation and trafficked rapidly into acidified compartments [72].

Available data therefore indicates that selected PE/PPE family members play important roles in subverting innate immune responses, and together with other bacterial mediators, may assist the pathogen in establishing itself within the host. Once this has occurred, PE/PPEs may then contribute to processes which allow the pathogen to persist within host tissues. Intriguingly, enzymatic functions have been assigned to 3 PE proteins: PE-*pgrs11* has been reported to be a functional phosphoglycerate mutase [55], while both PE-*pgrs63* (LipY, [43]) and PE11 (LipX, [73]) demonstrate lipase activity. The latter 2 proteins may therefore play a role in energy provision. It should be noted though that these are exceptional examples; they appear to have arisen as a result of recombination events which lead to functional divergence, and enzymatic activity is not predicted to be a general feature of the PE/PPE proteins.

Once established within their intracellular niche, there are a number of ways in which mycobacteria can limit engagement of the adaptive immune response, and the PE/PPE proteins may contribute to some of these mechanisms. The observation that PE-*pgrs* proteins bear some resemblance to the Epstein-Barr virus nuclear antigen (EBVNA) gave rise to speculation that, akin to the EBVNA, the PE-*pgrs* proteins may inhibit antigen processing [5]. This has subsequently been demonstrated for PE-*pgrs33* [48] and PE-*pgrs17* [74], supporting the idea that these proteins may assist in immune evasion by limiting antigen presentation, thereby preventing recognition and killing of mycobacteria-infected host cells.

Taken together, the observations described above suggest that different PE/PPE proteins may play distinct, but complementary roles as the infection progresses, acting in concert
to facilitate adaptation to the hostile host environment. Members of these families may be critical mediators of host responses which ultimately determine the outcome of infection. Understanding their individual and cumulative impact on host responses is an important undertaking which could provide the starting point for novel interventions. The large number and diverse effects of these proteins present some experimental challenges. Future explorations may therefore benefit from systems-level approaches to help unravel their biological role.

5. B and T Cell Recognition of PE/PPE Proteins

5.1. Humoral Immunity. The contribution of humoral responses to controlling *M. tuberculosis* infection has long been underappreciated. However, it is known that mycobacteria-specific antibodies can both influence mycobacterial dissemination and modulate potentially detrimental inflammatory tissue responses [75, 76]. It is increasingly recognized that B cells can exert an influence on T cells [77, 78] and are an important constituent of granuloma architecture [79]. B cells are thus likely to be more important in determining the outcome of infection with *M. tuberculosis* than previously supposed, and ignoring this aspect of the host immune response may restrict our understanding of TB immunopathology. In this context, PE/PPE family members are a potentially rich source of B cell epitopes, and a number of PE/PPE proteins may be surface exposed, increasing the likelihood that they could be targeted by the humoral response. Accordingly, numerous PE/PPE proteins have been shown to elicit B cell responses (Table S1). There is evidence for both members of the PE<PGRS and PPE_MPTR families that the highly repetitive domains are chiefly responsible for eliciting antibody responses. Delogu and Brennan were the first to demonstrate differential B and T cell targeting of the conserved N-terminal and highly repetitive, more variable, C-terminal of PE<PGRS33; DNA vaccination of mice with only the PE domain elicited predominantly cell-mediated immunity and subsequent protection against challenge, whereas a full-length PE_PGRS33 construct promoted a nonprotective, B cell-skewed response [80]. In agreement with these results, PPE_MPTR42 was found to elicit a primarily humoral response, directed toward the glycine and asparagine-rich repeat domain [81]. In other work, it was shown that the full-length PE_PGRS17 and PE_PGRS62 proteins were preferentially recognized in comparison to the PE-only versions [82]. Further elucidation of differential immune targeting of PE/PPE proteins could enable fine-tuning of new vaccine candidates.

5.2. PE/PPE Proteins as T Cell Immunogens. Cell-mediated immunity is especially important in the control of *M. tuberculosis* infection [83, 84]. Therefore, T cell antigens are of great interest for vaccine development and could form useful components of subunit DNA or protein vaccines or engineered into live recombinant vectors. Consequently, numerous studies have investigated the ability of PE/PPE proteins to elicit T cell responses (Table S1). For example, T cell expression cloning was successfully exploited to identify T cell immunogens in *M. tuberculosis*-sensitized individuals [85]; this relatively high-throughput approach resulted in the identification of the potent T cell antigen Mtb39a, which is encoded by Rv1196/ppel8. In subsequent work, this antigen has been evaluated as part of the polyprotein subunit vaccine candidate, Mtb72f, as described further below (Section 6.2). In addition to PPE18, at least 20 PE/PPE proteins have been reported to elicit CD4 and/or CD8 responses, either in the form of whole recombinant proteins or as individual peptides (Table S1). Together, these results suggest that PE/PPE proteins are worthy of further evaluation as potentially protective antigens for inclusion in new TB vaccine candidates.

Aside from the possible practical applications of PE/PPE-derived antigens (see Section 6), their high degree of immunogenicity could also provide some clues regarding their biological function. A recent study which combined multiple genome sequence comparisons with analysis of published immunogenicity data reported an unexpectedly high level of conservation of human T cell epitopes [86]. This runs counter to the existing dogma that antigenic targets will exhibit a relatively high degree of variation due to selection pressures imposed by host immune responses. Unfortunately, the high-throughput sequencing methodology used in the study imposes inherent technical limitations, which impact substantially on *pe/ppe* genes; due to the short sequence reads, highly repetitive, multicopy sequences are difficult to accurately assemble. As a result, PE/PPE proteins were excluded from their analysis. It is possible that some members of these protein families, in particular within the PE<PGRS and PPE_MPTR subgroups, could be exceptions to the described finding. However, our own recent work suggests that a large subset of the PE/PPE family, which is relatively well conserved across multiple clinical isolates, is also highly immunogenic (manuscript in preparation). The most conserved regions of the proteins are also the most well recognized, and even when PE/PPE amino acid sequences do vary, this does not necessarily impair epitope recognition by cross-reactive T cells (manuscript in preparation). Taken together, this suggests that at least some PE/PPE family members will fit the paradigm revealed by Comas et al. [86]. This raises the question of whether the high level of immunogenicity displayed by proteins such as the PE/PPEs confers a selective advantage on the pathogen. As speculated by others [87], it is possible that robust inflammatory responses lead to lung damage which could promote *M. tuberculosis* transmission. An alternative hypothesis is that these potent T cell antigens could provide a further means of immune evasion by overwhelming and misdirecting the adaptive immune response.

To date, there is little experimental data to support the contention that PE/PPE proteins contribute to antigenic variation in the conventional understanding of the phenomenon. However, there is substantial evidence that these proteins contribute to immune evasion via other important mechanisms, as described above.
6. Translational Applications

The findings described in the preceding sections have implications for both vaccine development and diagnostic tools.

6.1. Diagnostic Tools. In terms of new diagnostic tools, several highly immunogenic PE/PPEs have been identified, which could contribute to the development of antigen cocktails to be used in IFN-γ release assays or antibody-based tests. However, there are some caveats. Firstly, there is the issue of interspecies cross-reactivity—a number of PE/PPE proteins are present in mycobacteria outside of the M. tuberculosis complex [12] and are recognised immune targets [36, 81, 88, 89]. Therefore, antigens would need to be rigorously evaluated to ensure species-specificity. Secondly, although there are some indications that some PE/PPE-derived antigens may distinguish between vaccinated and nonvaccinated individuals, or between different forms of disease and/or stages of infection, [55, 82, 90–95], existing data suggests that differential diagnostic capability does not apply to all PE/PPE proteins [90, 91, 96]. Therefore their utility in distinguishing between active disease, latent infection and vaccinated individuals will likely be limited to selected family members, and would need rigorous validation in larger patient cohorts prior to clinical implementation.

6.2. Vaccines. PE/PPE proteins are a potentially rich source of T-cell antigens, and several of these have been assessed for possible inclusion in new vaccines [80, 97–102], Table S1. As mentioned above, the PPE18-based subunit vaccine candidate Mtbb72f, formulated with the adjuvant AS02A, has yielded promising results in multiple animal models [103, 104] and is now undergoing Phase I clinical trials [105, 106]. Similarly, evaluation of 2 polypeptide vaccine candidates which incorporate PPE_MPTR42 is at a relatively advanced stage. PPE_MPTR42 was shown to confer partial protection in mice when formulated with the TLR-9 agonist CpG [97]. The fusion protein ID83 (which incorporates Rv1813, Rv3620, and PPE_MPTR42) elicits protective immunity in mice [97], which can be modulated by use of different adjuvants and/or route of immunization [107]. In recent work, a similar fusion protein (ID93, which incorporates PPE_MPTR42, Rv1813, Rv3620 as well as a fourth antigen, Rv3619) has been shown to elicit protection against challenge with virulent M. tuberculosis in both mice and guinea pigs [108]. As it is likely that subunit vaccine candidates (either DNA or protein-based) will be introduced in the context of a BCG-prime/subunit boost regimen, it is appropriate to ask whether this be tested in this setting; importantly, ID93 offers enhanced protection in a BCG-prime/ID93-boost regimen in guinea pigs [108]. Furthermore, ID93 is immunogenic in cynomolgous macaques and elicits polyfunctional CD4 and CD8 responses in peripheral blood mononuclear cells from BCG-vaccinated humans [108]. Together, these promising preclinical results support further evaluation of ID93 in humans in Phase I clinical trials.

The protective capacity of additional PE/PPE-derived subunit candidates is also under investigation. For example, DNA vaccines based on PPE44 [99], PPE41 [100], and the PE domain of PE_PGRS33 [80] have all been shown to elicit protection in mice. In addition, PE_PGRS62- and PE20-derived DNA vaccines have been shown to reduce guinea pig bacterial lung burden by >0.5 log [101]. An alternative to the BCG prime/subunit boost approach is to heterologously express candidate antigens in a live vaccine vehicle, and thereby appropriately supplement/modulate immune responses. Wang et al. have explored this approach by coexpressing PPE57 and Ag85B in BCG and have demonstrated that the recombinant BCG strain elicits enhanced immunogenicity in mice [102]. However, it has yet to be determined whether this approach will result in improved protection.

In addition to their immunogenicity, other features of PE/PPE proteins may be beneficial to vaccine development efforts. For example, the PE domain is thought to be responsible for protein localization to the cell wall [44], and this property could be exploited to ensure optimal localization of PE/PPE-derived or other heterologous antigens in live recombinant vaccines. Secondly, selected PE/PPE proteins may be potent immune-modulators that could be exploited to fine-tune the immune response to enhance protective capabilities of vaccine antigens.

Although PE/PPE proteins show potential for exploitation in vaccine development efforts, several issues need to be considered. Firstly, many of the known PE/PPE immunogens have been identified on the basis of their ability to stimulate IFN-γ production. While this cytokine is clearly important for the control of TB, it is not necessarily the best predictor of protection against subsequent challenge [109]. The simultaneous production of other cytokines, such as IL-2, has been shown to be a significant component of a protective immune response [110]. Likewise, the phenotypic makeup of the responding cell population is also important; for example, the presence of antigen-specific central memory T cells correlates with protection [111]. Future antigen discovery and evaluation exercises therefore need to consider a broader cytokine profile, as well as the phenotype of the responding cell populations. A second point of caution is that the many of the immunogenic PE/PPE epitopes which have been identified are recognized during active infection, suggesting that the ability to mount an immune response against them does not necessarily confer protection.

However, with a more comprehensive understanding of what constitutes a protective immune response, it may be possible to fine-tune factors such as vaccination dose, timing, and formulation to accordingly modulate responses to vaccination. Finally, it will also be important to have a clearer understanding of PE/PPE function and possible adverse effects on host responses. For example, at least 3 PE_PGRS proteins, PPE_MPTR34, and PPE18 have all been shown to interact directly with surface receptors on host macrophages eliciting responses such as apoptosis and cytokine production [61, 63–65] that may not necessarily be desirable outcomes. Until we have a better understanding of the nuances of PE/PPE-host interactions, the use of these proteins as vaccine candidates should be cautiously approached.
Importantly, consideration is increasingly being given to the “real-world” setting in which new TB vaccine candidates will be tested and utilized. For example, epitope prediction tools can be used to assess the prevalence of peptides which are likely to bind MHC alleles found in the target population [112]. Also, multiple genome sequence comparisons can help to determine the degree of conservation of predicted MHC binding peptides in circulating mycobacterial strains [113]. Using Mtb72f as an example, McNamara et al. applied a combination of epitope prediction software packages to demonstrate that several MHC DRB1 alleles would have limited binding to predicted PPE18 epitopes [114]. They further showed that predicted binding peptides were relatively unconserved [114], in accordance with an earlier report [113]. On the basis of these results, it was suggested that Mtb72f might have limited efficacy in selected populations [114]. Although epitope prediction tools are still in need of refinement, in silico approaches such as these can be applied to prioritize antigen screening. They could also be used to predict the likely efficacy of selected vaccine candidates prior to undertaking lengthy and resource-intensive clinical trials.

7. Conclusions

More than a decade after their discovery, a cohesive understanding of the function of the PE/PPE proteins remains elusive. The large and complex families pose a number of experimental challenges. However, some interesting themes are emerging: several members of the family trigger a range of innate immune responses, and many are targets of the adaptive immune system. These families are a potentially rich source of diagnostic and vaccine antigens and could even find application as immunomodulatory agents. However, it will be critical to improve our understanding of their function and potential effects of these proteins on the host. Fundamental areas in need of attention include PE/PPE structural biology, identification of PE/PPE host targets, and bacterial interaction partners and an expanded understanding of the mechanisms whereby these proteins modulate host immune responses. Some of the experimental challenges posed by these large and complex proteins families could be addressed using approaches informed by the field of systems biology. Future investigations which exploit the wealth of mycobacterial genome sequence data in the context of our increasing understanding of host and pathogen biology may provide a platform for answering some of the intriguing questions surrounding these enigmatic proteins.

Acknowledgment

S. Sampson is funded by the Wellcome Trust.

References

[1] C. Dye and B. G. Williams, “The population dynamics and control of tuberculosis,” Science, vol. 328, no. 5980, pp. 856–861, 2010.
[2] P. W. M. Hermans, D. Van Soolingen, and J. D. A. Van Embden, “Characterization of a major polymorphic tandem repeat in Mycobacterium tuberculosis and its potential use in the epidemiology of Mycobacterium kansasii and Mycobacterium gordonae,” Journal of Bacteriology, vol. 174, no. 12, pp. 4157–4165, 1992.
[3] S. Poulet and S. T. Cole, “Characterization of the highly abundant polymorphic GC-rich-repetitive sequence (PGRS) present in Mycobacterium tuberculosis,” Archives of Microbiology, vol. 163, no. 2, pp. 87–95, 1995.
[4] R. Warren, M. Richardson, S. Sampson et al., “Genotyping of Mycobacterium tuberculosis with additional markers enhances accuracy in epidemiological studies,” Journal of Clinical Microbiology, vol. 34, no. 9, pp. 2219–2224, 1996.
[5] S. T. Cole, R. Brosch, J. Parkhill et al., “Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence,” Nature, vol. 393, no. 6685, pp. 537–544, 1998.
[6] C. R. McElroy, P. D. Van Helden, R. M. Warren, and N. C. G. Van Pittius, “Evidence for a rapid rate of molecular evolution at the hypervariable and immunogenic Mycobacterium tuberculosis PPE38 gene region,” BMC Evolutionary Biology, vol. 9, no. 1, article 237, 2009.
[7] A. Karboul, A. Mazza, N. C. Gey Van Pittius, J. L. Ho, R. Broussseau, and H. Mardassi, “Frequent homologous recombination events in Mycobacterium tuberculosis PE/PPE multigene families: potential role in antigenic variability,” Journal of Bacteriology, vol. 190, no. 23, pp. 7838–7846, 2008.
[8] S. Talarico, M. D. Cave, C. F. Marrs, B. Foxman, L. Zhang, and Z. Yang, “Variation of the Mycobacterium tuberculosis PLEPGRS33 gene among clinical isolates,” Journal of Clinical Microbiology, vol. 43, no. 10, pp. 4954–4960, 2005.
[9] S. Talarico, L. Zhang, C. F. Marrs et al., “Mycobacterium tuberculosis PLEPGRS16 and PLEPGRS26 genetic polymorphism among clinical isolates,” Tuberculosis, vol. 88, no. 4, pp. 283–294, 2008.
[10] S. Talarico, M. Donald Cave, B. Foxman et al., “Association of Mycobacterium tuberculosis PLEPGRS33 polymorphism with clinical and epidemiological characteristics,” Tuberculosis, vol. 87, no. 4, pp. 338–346, 2007.
[11] A. Cubillos-Ruiz, J. Morales, and M. M. Zambrano, “Analysis of the genetic variation in Mycobacterium tuberculosis strains by multiple genome alignments,” BMC Research Notes, vol. 1, article 110, 2008.
[12] N. C. Gey Van Pittius, S. L. Sampson, H. Lee, Y. Kim, P. D. van Helden, and R. M. Warren, “Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions,” BMC Evolutionary Biology, vol. 6, article 95, 2006.
[13] N. C. Gey Van Pittius, J. Gamieldien, W. Hide, G. D. Brown, R. J. Siezen, and A. D. Beyers, “The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria,” Genome Biology, vol. 2, no. 10, p. RESEARCH0044, 2001.
[14] A. S. Pym, P. Brodin, R. Brosch, M. Huereur, and S. T. Cole, “Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti,” Molecular Microbiology, vol. 46, no. 3, pp. 709–717, 2002.
[15] T. Hsu, S. M. Hingley-Wilson, B. Chen et al., “The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12420–12425, 2003.
A. M. Abdallah, T. Verboom, E. M. Weenderburg et al., "PPE and PE-PGRS proteins of Mycobacterium marinum are transported via the type VII secretion system ESX-5," Molecular Microbiology, vol. 73, no. 3, pp. 329–340, 2009.

S. M. Fortune, A. Jaeger, D. A. Sarracino et al., "Mutually dependent secretion of proteins required for mycobacterial virulence," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 30, pp. 10676–10681, 2005.

M. I. Voskuil, D. Schnappinger, R. Rutherford, Y. Liu, and G. M. I. Voskuil, D. Schnappinger, R. Rutherford, Y. Liu, and G. M., "Variable expression patterns of Mycobacterium tuberculosis PE-PGRS genes: evidence that PE-PGRS16 and PE-PGRS26 are inversely regulated in vivo," Journal of Bacteriology, vol. 188, no. 10, pp. 3721–3725, 2006.

J. Flores and C. Espitia, "Differential expression of PE and PE-PGRS genes in Mycobacterium tuberculosis strains," Gene, vol. 318, no. 1–2, pp. 75–81, 2003.

C. M. Sassetti, D. H. Boyd, and E. J. Rubin, "Genes required for mycobacterial growth defined by high density mutagenesis," Molecular Microbiology, vol. 48, no. 1, pp. 77–84, 2003.

C. M. Sassetti and E. J. Rubin, "Genetic requirements for mycobacterial survival during infection," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 22, pp. 12989–12994, 2003.

J. Rengarajan, B. R. Bloom, and E. J. Rubin, "Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 23, pp. 8327–8332, 2005.

M. K. Gupta, V. Subramanian, and J. S. Yadav, "Immuno-proteomic identification of secretory and subcellular protein antigens and functional evaluation of the secretome fraction of Mycobacterium immunogenum a newly recognized species of the Mycobacterium chelonae- Mycobacterium abscessus group," Journal of Proteome Research, vol. 8, no. 5, pp. 2319–2330, 2009.

M. Sani, E. N. G. Houben, J. Geurtsen et al., "Direct visualization by Cryo-EM of the mycobacterial capsular layer: a labile structure containing ESX-1-secreted proteins," PLoS Pathogens, vol. 6, no. 3, Article ID e1000794, 2010.

H. Målen, F. S. Berven, K. E. Fladmark, and H. G. Wiker, "Comprehensive analysis of exported proteins from Mycobacterium tuberculosis H37Rv," Proteomics, vol. 7, no. 10, pp. 1702–1718, 2007.

H. Målen, S. Pathak, T. Softeland, G. A. de Souza, and H. G. Wiker, "Definition of novel cell envelope associated proteins in Triton X-114 extracts of Mycobacterium tuberculosis H37Rv," BMC Microbiology, vol. 10, article 132, p. 132, 2010.

C. Demangel, P. Brodin, P. J. Cockle et al., "Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6," Infection and Immunity, vol. 72, no. 4, pp. 2170–2176, 2004.

V. Le Mogne, G. Robreau, C. Borot, J. L. Guesdon, and W. Mahana, "Expression, immunochemical characterization and localization of the Mycobacterium tuberculosis protein p27," Tuberculosis, vol. 85, no. 4, pp. 213–219, 2005.

K. C. Mishra, C. De Chastellier, Y. Narayana et al., "Functional role of the PE domain and immunogenicity of the Mycobacterium tuberculosis triacylglycerol hydrolase LipY," Infection and Immunity, vol. 76, no. 1, pp. 127–140, 2008.

A. Cascioferro, G. Delogu, M. Colone et al., "PE is a functional domain responsible for protein translocation and
localization on mycobacterial cell wall,” *Molecular Microbiology*, vol. 66, no. 6, pp. 1536–1547, 2007.

[45] S. Banu, N. Honoré, B. Saint-Joanis, D. Philpott, M. C. Prévost, and S. T. Cole, “Are the PE-PGRS proteins of *Mycobacterium tuberculosis* variable surface antigens?” *Molecular Microbiology*, vol. 44, no. 1, pp. 9–19, 2002.

[46] G. Delogu, C. Pusceddu, A. Bua, G. Fadda, M. J. Brennan, and S. Zanetti, “Rv1818c-encoded PE-PGRS protein of *Mycobacterium tuberculosis* is surface exposed and influences bacterial cell structure,” *Molecular Microbiology*, vol. 52, no. 3, pp. 725–733, 2004.

[47] S. L. Sampson, P. Lukey, R. M. Warren, P. D. Van Helden, M. Richardson, and M. J. Everett, “Expression, characterization and subcellular localization of the *Mycobacterium tuberculosis* PPE gene Rv1917c,” *Tuberculosis*, vol. 81, no. 5–6, pp. 305–317, 2001.

[48] M. J. Brennan and G. Delogu, “The PE multigene family: a ‘molecular mantra’ for mycobacteria,” *Trends in Microbiology*, vol. 10, no. 5, pp. 246–249, 2002.

[49] R. K. Choudhary, R. Pullakhandam, N. Z. Ehtesham, and S. E. Hasnain, “Expression and characterization of Rv2430c, a novel immunodominant antigen of *Mycobacterium tuberculosis*,” *Protein Expression and Purification*, vol. 36, no. 2, pp. 249–253, 2004.

[50] S. Daugelat, J. Kowall, J. Mattow et al., “The RD1 proteins of *Mycobacterium tuberculosis*: expression in Mycobacterium smegmatis and biochemical characterization,” *Microbes and Infection*, vol. 5, no. 12, pp. 1082–1095, 2003.

[51] S. Tundup, Y. Akhter, D. Thiagarajan, and S. E. Hasnain, “Clusters of PE and PPE genes of *Mycobacterium tuberculosis* are organized in operons: evidence that PE Rv2431c is co-transcribed with PPE Rv2430c and their gene products interact with each other,” *FEBS Letters*, vol. 380, no. 5, pp. 1285–1293, 2006.

[52] M. Strong, M. R. Sawaya, S. Wang, M. Phillips, D. Cascio, and D. Eisenberg, “Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from *Mycobacterium tuberculosis*,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 21, pp. 8060–8065, 2006.

[53] R. Riley, M. Pellegrini, and D. Eisenberg, “Identifying cognate binding pairs among a large set of paralogs: the case of PE/PPE proteins of *Mycobacterium tuberculosis*,” *PLoS Computational Biology*, vol. 4, no. 9, Article ID e1000174, 2008.

[54] A. M. Abdallah, N. D. L. Savage, M. Van Zon et al., “The ESX-5 secretion system of mycobacterial marinus modulates the macrophage response,” *Journal of Immunology*, vol. 181, no. 10, pp. 7166–7175, 2008.

[55] R. Chaturvedi, K. Bansal, Y. Narayana et al., “The multifunctional PE-PGRS11 protein from *Mycobacterium tuberculosis* plays a role in regulating resistance to oxidative stress,” *Journal of Biological Chemistry*, vol. 285, no. 40, pp. 30389–30403, 2010.

[56] A. Singh, D. Mai, A. Kumar, and A. J. C. Steyn, “Dissecting virulence pathways of *Mycobacterium tuberculosis* through protein-protein association,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 30, pp. 11346–11351, 2006.

[57] J. Teutschbein, G. Schumann, U. Möllmann, S. Grabley, S. T. Cole, and T. Munder, “A protein linkage map of the ESAT-6 secretion system 1 (ESX-1) of *Mycobacterium tuberculosis*,” *Microbiological Research*, vol. 164, no. 3, pp. 253–259, 2009.

[58] P. Brodin, I. Rosenkранds, P. Andersen, S. T. Cole, and R. Brosch, “ESAT-6 proteins: protective antigens and virulence factors?” *Trends in Microbiology*, vol. 12, no. 11, pp. 500–508, 2004.

[59] K. N. Balaji, G. Goyal, Y. Narayana, M. Srinivas, R. Chaturvedi, and S. Mohammad, “Apoptosis triggered by Rv1818c, a PE family gene from *Mycobacterium tuberculosis* is regulated by mitochondrial intermediates in T cells,” *Microbes and Infection*, vol. 9, no. 3, pp. 271–281, 2007.

[60] L. Ramakrishnan, N. A. Federzien, and S. Falkow, “Granuloma-specific expression of *Mycobacterium* virulence proteins from the glycin-rich PE-PGRS family,” *Science*, vol. 288, no. 5470, pp. 1436–1439, 2000.

[61] S. Basu, S. K. Pathak, A. Banerjee et al., “Execution of macrophage apoptosis by PE-PGRS33 of *Mycobacterium tuberculosis* is mediated by toll-like receptor 2-dependent release of tumor necrosis factor-α,” *Journal of Biological Chemistry*, vol. 282, no. 2, pp. 1039–1050, 2007.

[62] V. Dheenadhayalan, G. Delogu, and M. J. Brennan, “Expression of the PE-PGRS 33 protein in Mycobacterium smegmatis triggers necrosis in macrophages and enhanced mycobacterial survival,” *Microbes and Infection*, vol. 8, no. 1, pp. 262–272, 2006.

[63] K. Bansal, S. R. Elluru, Y. Narayana et al., “PE-PGRS antigens of *Mycobacterium tuberculosis* induce maturation and activation of human dendritic cells,” *Journal of Immunology*, vol. 184, no. 7, pp. 3495–3504, 2010.

[64] S. Nair, P. A. Ramaswamy, S. Ghosh et al., “The PPE18 of *Mycobacterium tuberculosis* interacts with TLR2 and activates IL-10 induction in macrophage,” *Journal of Immunology*, vol. 183, no. 10, pp. 6269–6281, 2009.

[65] K. Bansal, A. Y. Sinha, D. S. Ghospade et al., “Src homology 3-interacting domain of Rv1917c of *Mycobacterium tuberculosis* induces selective maturation of human dendritic cells by regulating PI3K-MAPK-NF-kB signaling and drives Th2 immune responses,” *Journal of Biological Chemistry*, vol. 285, no. 47, pp. 36521–36522, 2010.

[66] M. J. Brennan, G. Delogu, Y. Chen et al., “Evidence that mycobacterial PE-PGRS proteins are cell surface constituents that influence interactions with other cells,” *Infection and Immunity*, vol. 69, no. 12, pp. 7326–7333, 2001.

[67] P. K. Mehta, A. K. Pandey, S. Subbian et al., “Identification of Mycobacterium marinum macrophage infection mutants,” *Microbial Pathogenesis*, vol. 40, no. 4, pp. 139–151, 2006.

[68] P. P. Singh, M. Parra, N. Cadieux, and M. J. Brennan, “A comparative study of host response to three *Mycobacterium tuberculosis* PE_PGRS proteins,” *Microbiology*, vol. 154, no. 11, pp. 3469–3479, 2008.

[69] S. Jha, L. Danelishvili, D. Wagner et al., “Virulence-related Mycobacterium avium MAV_{2928} gene is associated with vacuole remodeling in macrophages,” *BMC Microbiology*, vol. 10, article 100, p. 100, 2010.

[70] Y. Li, E. Miltner, M. Wu, M. Petrofsky, and L. E. Bermudez, “A Mycobacterium avium PPE gene is associated with the ability of the bacterium to grow in macrophages and virulence in mice,” *Cellular Microbiology*, vol. 7, no. 4, pp. 539–548, 2005.

[71] G. R. Stewart, J. Patel, B. D. Robertson, A. Rae, and D. B. Young, “Mycobacterial mutants with defective control of phagosomal acidification,” *PLoS Pathogens*, vol. 1, no. 3, article e33, pp. 0269–0278, 2005.

[72] P. Brodin, Y. Poquet, F. Levillain et al., “High content phenotypic cell-based visual screen identifies *Mycobacterium tuberculosis* acyltrehalose-containing glycolipids involved in phagosome remodeling,” *PLoS Pathogens*, vol. 6, no. 9, 2010.
[73] C. Deb, J. Daniel, T. D. Sirakova, B. Abomoelak, V. S. Dubey, and P. E. Kolattukudy, "A novel lipase belonging to the hormone-sensitive lipase family induced under starvation to utilize stored triacylglycerol in Mycobacterium tuberculosis," *Journal of Biological Chemistry*, vol. 281, no. 7, pp. 3866–3875, 2006.

[74] K. W. Koh, N. Lehming, and G. T. Seah, “Degradation-resistant protein domains limit host cell processing and immune detection of mycobacteria,” *Molecular Immunology*, vol. 46, no. 7, pp. 1312–1318, 2009.

[75] C. M. Bosio, D. Gardner, and K. L. Elkins, “Infection of B cell-deficient mice with CDC 1551, a clinical isolate of Mycobacterium tuberculosis: delay in dissemination and development of lung pathology,” *Journal of Immunology*, vol. 164, no. 12, pp. 6417–6425, 2000.

[76] P. J. Maglione, J. Xu, and J. Chan, "B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis," *Journal of Immunology*, vol. 178, no. 11, pp. 7222–7234, 2007.

[77] F. E. Lund, M. Hollifield, K. Schuer, J. L. Lines, T. D. Randall, and B. A. Garvy, "B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection," *Journal of Immunology*, vol. 176, no. 10, pp. 6147–6154, 2006.

[78] H. Shen, J. K. Whitmire, X. Fan, D. J. Shedlock, S. M. Kaech, and R. Ahmed, "A specific role for B cells in the generation of CD8 T cell memory by recombiant Listeria monocytogenes," *Journal of Immunology*, vol. 170, no. 3, pp. 1443–1451, 2003.

[79] M. C. Tsai, S. Chakravarty, G. Zhu et al., “Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension,” *Cellular Microbiology*, vol. 8, no. 2, pp. 218–232, 2006.

[80] G. Delogu and M. J. Brennan, "Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis," *Infection and Immunity*, vol. 69, no. 9, pp. 5606–5611, 2001.

[81] R. Chakhaiyar, Y. Nagalakshmi, B. Aruna, K. J. R. Murthy, V. M. Katoch, and S. E. Hasnain, “Regions of high antigenicity within the hypothetical PPE major polymorphic tandem repeat open-reading frame, Rv2608, show a differential humoral response and a low T cell response in various categories of patients with tuberculosis,” *Journal of Infectious Diseases*, vol. 190, no. 7, pp. 1237–1244, 2004.

[82] W. K. Kah, E. S. Shu, and T. S. Geok, “Strong antibody responses to Mycobacterium tuberculosis PE-PGRS62 protein are associated with latent and active tuberculosis,” *Infection and Immunity*, vol. 77, no. 8, pp. 3337–3343, 2009.

[83] A. M. Caruso, N. Serbina, E. Klein, K. Triebold, B. R. Bloom, and J. L. Flynn, “Mice deficient in CD4 T cells have only transiently diminished levels of IFN-γ, yet succumb to tuberculosis,” *Journal of Immunology*, vol. 162, no. 9, pp. 5407–5416, 1999.

[84] J. L. Flynn, M. M. Goldstein, K. J. Triebold, B. Koller, and B. R. Bloom, “Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 89, no. 24, pp. 12013–12017, 1992.

[85] D. C. Dillon, M. R. Alderson, C. H. Day et al., “Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mbt39 gene family,” *Infection and Immunity*, vol. 67, no. 6, pp. 2941–2950, 1999.

[86] I. Comas, J. Chakravartti, P. M. Small et al., “Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved,” *Nature Genetics*, vol. 42, no. 6, pp. 498–503, 2010.

[87] A. L. Graham, J. E. Allen, and A. F. Read, “Evolutionary causes and consequences of immunopathology,” *Annual Review of Ecology, Evolution, and Systematics*, vol. 36, pp. 373–397, 2005.

[88] R. Nagata, Y. Muneta, K. Yoshihara, Y. Yokomizo, and Y. Mori, “Expression cloning of gamma interferon-inducing antigens of Mycobacterium avium subspecies paratuberculosis,” *Infection and Immunity*, vol. 73, no. 6, pp. 3778–3782, 2005.

[89] M. Parra, N. Cadieux, T. Pickett, V. Dheenadhayalan, and M. J. Brennan, “A PE protein expressed by Mycobacterium avium is an effective T-cell immunogen,” *Infection and Immunity*, vol. 74, no. 1, pp. 786–789, 2006.

[90] P. J. Cockle, S. V. Gordon, A. Lalvani, B. M. Buddle, R. G. Hewinson, and H. M. Vordermeier, “Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics,” *Infection and Immunity*, vol. 70, no. 12, pp. 6996–7003, 2002.

[91] G. C. Ireton, R. Greenwald, H. Liang, J. Esfandiari, K. P. Lyashchenko, and S. G. Reed, “Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value,” *Clinical and Vaccine Immunology*, vol. 17, no. 10, pp. 1539–1547, 2010.

[92] N. Khan, K. Alam, S. Nair, V. L. Valluri, K. J. R. Murthy, and S. Mukhopadhyay, “Association of strong immune responses to PPE protein Rv1168c with active tuberculosis,” *Clinical and Vaccine Immunology*, vol. 15, no. 6, pp. 974–980, 2008.

[93] K. K. Singh, Y. Dong, S. A. Patibandla, D. N. McMurray, V. K. Arora, and S. Laal, “Immunogenicity of the Mycobacterium tuberculosis PPE55 (Rv3347c) protein during incipient and clinical tuberculosis,” *Infection and Immunity*, vol. 73, no. 8, pp. 5004–5014, 2005.

[94] K. K. Singh, X. Zhang, A. S. Patibandla, P. Chien, and S. Laal, “Antigens of Mycobacterium tuberculosis expressed during preclinical tuberculosis: serological immunodominance of proteins with repetitive amino acid sequences,” *Infection and Immunity*, vol. 69, no. 6, pp. 4185–4191, 2001.

[95] H. Zhang, J. Wang, J. Lei et al., “PPE protein (Rv3425) from DNA segment RD11 of Mycobacterium tuberculosis: a potential B-cell antigen used for serological diagnosis to distinguish vaccinated controls from tuberculosis patients,” *Clinical Microbiology and Infection*, vol. 13, no. 2, pp. 139–145, 2007.

[96] K. Weldingh, I. Rosenkranz, L. M. Okkels, T. M. Doherty, and P. Andersen, “Assessing the serodiagnostic potential of 35 Mycobacterium tuberculosis proteins and identification of four novel serological antigens,” *Journal of Clinical Microbiology*, vol. 43, no. 1, pp. 57–65, 2005.

[97] S. Bertholet, G. C. Ireton, M. Kahn et al., “Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis,” *Journal of Immunology*, vol. 181, no. 11, pp. 7948–7957, 2008.

[98] J. Campuzano, D. Aguilar, K. Arriaga et al., “The PGRS domain of Mycobacterium tuberculosis. PE_PGRS Rv1759c antigen is an efficient subunit vaccine to prevent reactivation in a murine model of chronic tuberculosis,” *Vaccine*, vol. 25, no. 18, pp. 3722–3729, 2007.

[99] M. Romano, I. Rindi, H. Korf et al., “Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing..."
PPE44 (Rv2770c), "Vaccine, vol. 26, no. 48, pp. 6053–6063, 2008.

[100] Y. A. W. Skeiky, P. J. Ovendale, S. Jen et al., "T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection," Journal of Immunology, vol. 165, no. 12, pp. 7140–7149, 2000.

[101] J. Vipond, R. Vipond, E. Allen-Vercoe et al., “Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge,” Vaccine, vol. 24, no. 37–39, pp. 6340–6350, 2006.

[102] J. L. Wang, YA. Qie, B. D. Zhu et al., “Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice,” Medical Microbiology and Immunology, vol. 198, no. 1, pp. 5–11, 2009.

[103] S. G. Reed, R. N. Coler, W. Dalemans et al., “Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 7, pp. 2301–2306, 2009.

[104] L. Tsenva, R. Harbacheuski, A. L. Moreira et al., “Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis,” Infection and Immunity, vol. 74, no. 4, pp. 2392–2401, 2006.

[105] I. Leroux-Roels, G. Leroux-Roels, O. Ofori-Anyinam et al., “Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02A candidate tuberculosis vaccine in purified protein derivative-negative adults,” Clinical and Vaccine Immunology, vol. 17, no. 11, pp. 1763–1771, 2010.

[106] K. Von Eschen, R. Morrison, M. Braun et al., “The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans,” Human Vaccines, vol. 5, no. 7, pp. 475–482, 2009.

[107] S. L. Baldwin, S. Bertholet, M. Kahn et al., “Intradermal immunization improves protective efficacy of a novel TB vaccine candidate,” Vaccine, vol. 27, no. 23, pp. 3063–3071, 2009.

[108] S. Bertholet, G. C. Ireton, D. J. Ordway et al., “A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis,” Science Translational Medicine, vol. 2, no. 53, Article ID 53ra74, 2010.

[109] H.-W. Mittrücker, U. Steinhoff, A. Köhler et al., “Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 30, pp. 12434–12439, 2007.

[110] A. Lalvani and K. A. Millington, “T cells and tuberculosis: beyond interferon-γ,” Journal of Infectious Diseases, vol. 197, no. 7, pp. 941–943, 2008.

[111] L. M. Connor, M. C. Harvie, F. J. Rich et al., “A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination,” European Journal of Immunology, vol. 40, no. 9, pp. 2482–2492, 2010.

[112] M. G. Chaïtra, S. Hariaraputran, N. R. Chandra, M. S. Shaila, and R. Nayak, "Defining putative T cell epitopes from PE and PPE families of proteins of Mycobacterium tuberculosis with vaccine potential," Vaccine, vol. 23, no. 10, pp. 1265–1272, 2005.

[113] A. M. Hebert, S. Talarico, D. Yang et al., “DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy,” Infection and Immunity, vol. 75, no. 12, pp. 5798–5805, 2007.

[114] L. A. McNamara, Y. He, and Z. Yang, "Using epitope predictions to evaluate efficacy and population coverage of the Mtb72F vaccine for tuberculosis," BMC Immunology, vol. 11, article 18, 2010.